21414779

Source:http://linkedlifedata.com/resource/pubmed/id/21414779

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0140080, umls-concept:C0202220, umls-concept:C0243077, umls-concept:C0597357, umls-concept:C1880355
pubmed:issue	8
pubmed:dateCreated	2011-4-4
pubmed:abstractText	The insulin-like growth factor-1 receptor (IGF-1R) plays an important role in the regulation of cell growth and differentiation, and in protection from apoptosis. IGF-1R has been shown to be an appealing target for the treatment of human cancer. Herein, we report the synthesis, structure-activity relationships (SAR), X-ray cocrystal structure and in vivo tumor study results for a series of 2,4-bis-arylamino-1,3-pyrimidines.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9107377
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines, http://linkedlifedata.com/resource/pubmed/chemical/Quinolines, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, IGF Type 1
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	1464-3405
pubmed:author	pubmed-author:BuchananJohn LJL, pubmed-author:CarneyDavid PDP, pubmed-author:ChaffeeStuart CSC, pubmed-author:ChaiLillyL, pubmed-author:CupplesRodR, pubmed-author:EpsteinLinda FLF, pubmed-author:EschJ FJF, pubmed-author:GallantPaulP, pubmed-author:GuYanY, pubmed-author:HarmangeJean-ChristopheJC, pubmed-author:HodgeKathyK, pubmed-author:HoukBrett EBE, pubmed-author:HuangXinX, pubmed-author:JonaJananJ, pubmed-author:JosephSmritiS, pubmed-author:JunH ToniHT, pubmed-author:KumarRakeshR, pubmed-author:LuJohnJ, pubmed-author:MengesTomT, pubmed-author:MorrisonMichael JMJ, pubmed-author:NewcombJohn RJR, pubmed-author:NovakPerry MPM, pubmed-author:RadinskyRobertR, pubmed-author:RosePaul EPE, pubmed-author:SawantSatinS, pubmed-author:SunJi-RongJR, pubmed-author:SurapaneniSekharS, pubmed-author:TurciSusan MSM, pubmed-author:XuKeyangK, pubmed-author:YanezEvelynE, pubmed-author:ZhaoHuilinH, pubmed-author:ZhuXiaotianX, pubmed-author:van der PlasSimonS
pubmed:copyrightInfo	Copyright © 2011 Elsevier Ltd. All rights reserved.
pubmed:issnType	Electronic
pubmed:day	15
pubmed:volume	21
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2394-9
pubmed:meshHeading	pubmed-meshheading:21414779-Animals, pubmed-meshheading:21414779-Binding Sites, pubmed-meshheading:21414779-Crystallography, X-Ray, pubmed-meshheading:21414779-Drug Evaluation, Preclinical, pubmed-meshheading:21414779-Humans, pubmed-meshheading:21414779-Mice, pubmed-meshheading:21414779-Protein Kinase Inhibitors, pubmed-meshheading:21414779-Pyrimidines, pubmed-meshheading:21414779-Quinolines, pubmed-meshheading:21414779-Receptor, IGF Type 1, pubmed-meshheading:21414779-Structure-Activity Relationship, pubmed-meshheading:21414779-Xenograft Model Antitumor Assays
pubmed:year	2011
pubmed:articleTitle	Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.
pubmed:affiliation	Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA. john.buchanan@amgen.com
pubmed:publicationType	Journal Article